Particularly weak Q2, mainly due to North America. We cut '24e-'26e sales by 2-3% on the Q2 miss. Large deal signings in H2e and easy Q3 comps, reiterate BUY.
Weak Q1 amid tough comps and no order announcements, but sales to improve with US defence budget now approved. We cut '24-'26e EBIT by 3-1 on slightly higher costs: keep BUY.